111 Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

111 Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,430	Closed	-$307K	–	505
2026 Q1	$307K	Buy	+5,430	New	+$317K	0.08%	245
2025 Q4	–	Sell	-6,337	Closed	-$343K	–	355
2025 Q3	$343K	Buy	+6,337	New	+$362K	0.07%	290

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

111 Capital's BMRN Position: Q2 2026 in Review

111 Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 5,430 shares — an estimated $307K sold.

111 Capital first reported a position in BMRN in Q3 2025 and held it in 2 quarters. The position peaked at $343K in Q3 2025. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

111 Capital reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
111 Capital sold 5,430 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $307K.
111 Capital first reported a position in BioMarin Pharmaceuticals in Q3 2025 and held it in 2 quarters.
111 Capital's BioMarin Pharmaceuticals position peaked at $343K in Q3 2025.
561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on 111 Capital's 13F filing for Q2 2026, filed 5 Aug 2026.